Navigation Links
Cerecor Acquires Rights to NR2B Receptor Antagonist from Merck
Date:4/19/2013

BALTIMORE, April 19, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

There is a growing body of evidence to support the hypothesis that NMDA receptors are involved in the pathology of depression, including reports in the literature of rapid improvement of depression following intravenous administration of ketamine, an NMDA antagonist. MK-0657 is a novel potent and selective NR2B antagonist, initially developed by Merck for the treatment of Parkinson's disease.

"MK-0657 is a potential first-in-class, best-in-class, oral medication that is complementary to existing treatments in depressed patients who have failed to respond to available therapies. We are particularly interested in the potential to rapidly reduce depressive symptoms, including suicidal ideation, in these severely affected patients," stated Dr. James Vornov , Cerecor's Sr. VP of Clinical Development and Regulatory Affairs.

Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of MK-0657.  License consideration includes milestone payments and royalties consistent with clinical stage licenses in neuroscience. Cerecor anticipates completing the technology transfer activities by mid-2013 and thereafter initiating clinical trials.

"We are delighted that Merck has chosen Cerecor to help realize the value of an innovative asset such as MK-0657," added Dr. Blake Paterson ,
'/>"/>

SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerecor Acquires Rights to Merck COMT Inhibitors
2. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
3. Dr. Magnus Persson Joins Cerecors Board of Directors
4. Cerecor Announces Initiation of CLIN01-002-A
5. MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems
6. Numotion Acquires Ultimate Mobility, Inc.
7. VWR International, LLC Acquires Basan UK Limited
8. Kimberly-Clark Health Care Acquires Anesthesia Business from Life-Tech
9. VWR International, LLC Acquires Prolab Laboratuar Teknolojileri Limited In Turkey
10. Oncologix Tech Inc. (OCLG) Acquires Dotolo; Gains Ongoing Sales, Patents, and New CEO
11. Kimberly-Clark Heath Care Acquires Anesthesia Business from Life-Tech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
(Date:7/30/2015)... OSAKA, Japan , July 30, 2015 /PRNewswire/ ... completion of the study to fulfill the post-marketing ... from the Pan European Multi-Database Bladder Cancer ... multi-database retrospective matched cohort study, conducted in four ... (pioglitazone HCI) with up to 10 years of ...
(Date:7/30/2015)... 2015   Sentrian , the Remote Patient ... recently received confirmation from the Food & Drug ... solution meets the definition of a "medical device" ... Discretion." The designation identifies medical ... regulatory requirements at this time" and clears the ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
... 29, 2011 Professional and Trade Relations groups play ... to professional, payer and patient groups. However, today,s restrictive ... PTR activities - thus creating pressure on PTR groups ... optimize their impact.   Recognizing changing needs ...
... April 29, 2011 Phil Hagerman, president and CEO of ... Leader & Innovator of the Year. The award ... which co-sponsors the annual award along with Grant Thornton LLP, ... and Technology Report. Hagerman was chosen from among 45 nominees ...
Cached Medicine Technology:Professional Relations Excellence Outlined in New Best Practices, LLC Report 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 3
(Date:7/30/2015)... & Caicos Islands, BWI (PRWEB) , ... July 31, 2015 , ... The Venetian on ... for fall, 2015. Guests who stay at the Venetian will save 40% on their ... The fall months are always quiet in the Turks & Caicos, providing a chance to ...
(Date:7/30/2015)... ... 30, 2015 , ... The Clinical Data Interchange Standards Consortium ... announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis ... . These three Therapeutic Area (TA) standards were developed per the CDISC global, ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will ... site. As discussed in a June 8, 2015 article published by Nasdaq , ... have been caused by its computer-driven cars, which such industry players as Tesla CEO ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2
... patients would bear the brunt of a Government proposal to ... ,This plan would very likely push up the ... to pay for their medication facing a greater financial burden, ... it ensures that Australians are able to access the ...
... avian influenza since 2005, state media said Friday. ... a 29-year-old man has been infected with the deadly H5N1 ... to Vietnam News Agency. ,The man, from Vinh ... from high fever and breathing difficulties on May 10. He ...
... improve global public health, Weill Cornell Medical College students ... the World Health Organization's (WHO) list of essential ... to choose which high-priority drugs should be supplied to ... chapter of Universities Allied for Essential Medicines (UAEM) answered ...
... that they have identified a gene that needs to be ... ,The gene detected by the researchers ... of the well-known breast cancer gene BRCA1. ,The ... of the University of Pennsylvania and the Dana-Farber Cancer Institute, ...
... that appetite-regulating peptides leptin and ghrelin influence alcohol cravings ... powerful urge to drink, is an important contributor to ... Otto Lesch of the University of Vienna has divided ... that refers to people with heavy alcohol withdrawals who ...
... has opened one of the few clinics in the ... Down Syndrome. Because of improvements in diagnosis, treatment ... patients are now routinely living into adulthood, and have ... of the population. ,Childrens hospitals, pediatricians and our ...
Cached Medicine News:Health News:Medical College Students Help Change Global Health Policy 2Health News:Scientists Identify New Breast Cancer Gene 2Health News:Appetite-regulating Peptides Influence Alcohol Cravings 2Health News:Adult Down Syndrome Clinic Opened at UAB 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: